NCT01687075 - CRE8 in All Comers Patients | Biotech Hunter

Enrollment

215

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

August 31, 2014

Conditions

Consecutive Subjects Who Are Suitable for a CoronaryAngioplasty of de Novo Lesion(s) in Native CoronaryArteries Should be Screened for Eligibility.A Total Number of 200 Patients Fulfilling the SelectionCriteria and Willing to Sign the Informed Consent Shouldbe Enrolled in the Trial.

Interventions

DEVICE

CR8 a drug eluting coronary stent

a drug eluting coronary device, made of Cobalt-Chromium alloy and integrally coated with i-Carbofilm™, loaded with formulated Sirolimus

Trial Locations (1)

64329

Tel Aviv Sourasky Medical Center, Tel Aviv

All Listed Sponsors

lead

Tel-Aviv Sourasky Medical Center

OTHER_GOV